Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.

Journal of medicinal chemistry - 10 Sept 2015

Estrada Anthony A, Sweeney Zachary K

Abstract excerpt

There is an urgent need for the development of Parkinson's disease (PD) treatments that can slow disease progression. The leucine-rich repeat kinase 2 (LRRK2) protein has been genetically and functionally linked to PD, and modulation of LRRK2 enzymatic activity has been proposed as a novel therapeutic strategy. In this review, we describe the bioactivity of selected small molecules that have been used to inhibit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Brain
Share to Guanosine Triphosphate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to Parkinson Disease

Share to Permeability

Share to Protein Conformation

Share to Protein Serine-Threonine Kinases

Source

Identifiers

PMID: 25915084
DOI: 10.1021/acs.jmedchem.5b00261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.PMID 25915084Read ↗

Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsSemantic proximity Read ↗

The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read ↗

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.Semantic proximity Read ↗

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.Semantic proximity Read ↗

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read ↗

Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).Semantic proximity Read ↗

Screening for chemical modulators for LRRK2.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)Semantic proximity Read ↗

Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.